Related Experiment Video
Updated: May 6, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Checkpoint blocking antibodies in cancer immunotherapy
Chrisann Kyi1, Michael A Postow2
1Department of Medicine, New York Presbyterian Hospital Cornell, 525 E 68th St., New York, NY 10065, United States.
Abstract:
Cancers can be recognized by the immune system, and the immune system may regulate and even eliminate tumors. The development of checkpoint blocking antibodies, such as those directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 receptor (PD-1), have demonstrated significant recent promise in the treatment of an expanding list of malignancies. While both CTLA-4 and PD-1 function as negative regulators, each plays a non-redundant role in modulating immune responses. CTLA-4 attenuates the early activation of naïve and memory T cells. In contrast, PD-1 is primarily involved in modulating T cell activity in peripheral tissues via interaction with its ligands, PD-L1 and PD-L2. Unfortunately, not all patients respond to these therapies, and evaluation of biomarkers associated with clinical outcomes is ongoing. This review will examine the efficacy, toxicities, and clinical development of checkpoint blocking antibodies, including agents already approved by the US Food and Drug Administration (anti-CTLA-4, ipilimumab) or in development (anti-PD-1, PD-L1). Future studies will likely uncover new promising immunologic checkpoints to target alone or in combination with other immunotherapeutic approaches, chemotherapy, radiotherapy, and small molecules.
Insights
Immune checkpoint inhibitors, like anti-CTLA-4 and anti-PD-1 therapies, show promise in cancer treatment by modulating T cell responses. Ongoing research aims to improve patient outcomes and identify new targets for combination therapies.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- The immune system can identify and eliminate cancerous tumors.
- Checkpoint blocking antibodies targeting CTLA-4 and PD-1 have emerged as promising cancer treatments.
- CTLA-4 and PD-1 are distinct negative regulators of immune responses.
Purpose of the Study:
- To review the efficacy, toxicities, and clinical development of checkpoint blocking antibodies.
- To discuss approved agents (anti-CTLA-4, ipilimumab) and those in development (anti-PD-1, PD-L1).
- To explore future directions in targeting immunologic checkpoints.
Main Methods:
- Review of clinical data and literature on checkpoint inhibitors.
- Examination of the mechanisms of action for CTLA-4 and PD-1.
- Analysis of current and future therapeutic strategies.
Main Results:
- Checkpoint inhibitors have shown significant promise in treating various malignancies.
- CTLA-4 primarily affects T cell activation, while PD-1 modulates T cell activity in peripheral tissues.
- Not all patients respond to current therapies, necessitating biomarker research.
Conclusions:
- Checkpoint blocking antibodies represent a significant advancement in cancer immunotherapy.
- Further research is needed to optimize patient selection and combination strategies.
- New immunologic checkpoints offer potential for future therapeutic development.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:34Inhibition of Cdk Activity
02:34Inhibition of CDK Activity
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...